223 related articles for article (PubMed ID: 16051786)
41. Drug development. A European-inspired renaissance for China's drug industry?
Xin H
Science; 2007 Jul; 317(5837):436-7. PubMed ID: 17656689
[No Abstract] [Full Text] [Related]
42. Antibacterial drug discovery: is small pharma the solution?
Boggs AF; Miller GH
Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():32-6. PubMed ID: 15522038
[TBL] [Abstract][Full Text] [Related]
43. Drug screening--beyond the bottleneck.
Dove A
Nat Biotechnol; 1999 Sep; 17(9):859-63. PubMed ID: 10471925
[TBL] [Abstract][Full Text] [Related]
44. Antibiotic development: a victim of market forces?
Tillotson GS
IDrugs; 2008 May; 11(5):340-6. PubMed ID: 18465675
[TBL] [Abstract][Full Text] [Related]
45. India's drug tests.
Padma TV
Nature; 2005 Jul; 436(7050):485. PubMed ID: 16049471
[No Abstract] [Full Text] [Related]
46. [New methods in pharmaceutical research: combinatorial chemistry and high throughput screening].
Schirlin D; Galvan M; Le Fur G
Bull Acad Natl Med; 2007; 191(4-5):727-36; discussion 736-7. PubMed ID: 18225426
[TBL] [Abstract][Full Text] [Related]
47. Drug development. Biotech thinking comes to academic medical centers.
Alper J
Science; 2003 Feb; 299(5611):1303-5. PubMed ID: 12610271
[No Abstract] [Full Text] [Related]
48. Venturing into drug discovery.
Steinmetz M
Nat Biotechnol; 1998 May; 16 Suppl():17. PubMed ID: 9591255
[No Abstract] [Full Text] [Related]
49. Creating effective medicinal chemistry collaborations in drug discovery.
Giardina GA; Raveglia LF
Future Med Chem; 2009 Apr; 1(1):3-6. PubMed ID: 21426065
[No Abstract] [Full Text] [Related]
50. [Drug targets: identification and evaluation].
Mikkelsen JD
Ugeskr Laeger; 2005 May; 167(20):2156-60. PubMed ID: 15987072
[No Abstract] [Full Text] [Related]
51. Independent medical research.
van der Meer JW; de Gier AM; van Swaaij WP; Katan MB
Neth J Med; 2007 Apr; 65(4):124-6. PubMed ID: 17452759
[No Abstract] [Full Text] [Related]
52. Deals landscape: notable deals in the pharmaceutical industry in the first quarter of 2008.
Shumoogam J; Al-Shamahi A
IDrugs; 2008 May; 11(5):351-5. PubMed ID: 18465677
[TBL] [Abstract][Full Text] [Related]
53. Prologue: chirality in the pharmaceutical industry.
Caldwell J; Berova N; McConnell O
Chirality; 2007 Sep; 19(9):657. PubMed ID: 17657706
[No Abstract] [Full Text] [Related]
54. A new era of hope for the world's most neglected diseases.
The
PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790
[TBL] [Abstract][Full Text] [Related]
55. Michigan lab axed as Pfizer cuts costs.
Wadman M
Nature; 2007 Feb; 445(7127):466-7. PubMed ID: 17268437
[No Abstract] [Full Text] [Related]
56. Victoria, a springboard for a research based pharmaceutical industry.
Windle HK
Australas Biotechnol; 1991 Oct; 1(2):88-91. PubMed ID: 1367647
[No Abstract] [Full Text] [Related]
57. Integrating molecular design resources within modern drug discovery research: the Roche experience.
Stahl M; Guba W; Kansy M
Drug Discov Today; 2006 Apr; 11(7-8):326-33. PubMed ID: 16580974
[TBL] [Abstract][Full Text] [Related]
58. Commentary: an independent voice?: conflicts of interest and research on ethical, legal and social issues.
Caulfield T
Health Law Rev; 2005; 13(2-3):114-6. PubMed ID: 16459424
[No Abstract] [Full Text] [Related]
59. Bench research versus clinical trials: where should Canadian grant dollars go?
Lee PC
CMAJ; 2000 Mar; 162(6):754, 756. PubMed ID: 10777330
[No Abstract] [Full Text] [Related]
60. [Pharmacogenetic-assisted drug development. Regulatory aspects from the viewpoint of the Medical Products Agency].
Theilade MD
Ugeskr Laeger; 2005 May; 167(20):2146-50. PubMed ID: 15987069
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
